Pictet Asset Management’s Legend Biotech LEGN Stock Holding History

Pictet Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.73M	Sell	94,397 -4,324	-4%	-$117K	﹤0.01%	864
2026 Q1	$1.79M	Sell	98,721 -12,744	-11%	-$243K	﹤0.01%	926
2025 Q4	$2.42M	Buy	111,465 +18	+0%	+$516	﹤0.01%	872
2025 Q3	$3.63M	Buy	111,447 +13,050	+13%	+$482K	﹤0.01%	824
2025 Q2	$3.49M	Sell	98,397 -83,956	-46%	-$2.72M	﹤0.01%	821
2025 Q1	$6.29M	Buy	182,353 +92,684	+103%	+$3.32M	0.01%	759
2024 Q4	$2.92M	Buy	89,669 +2,223	+3%	+$92.1K	﹤0.01%	866
2024 Q3	$4.26M	Buy	87,446 +124	+0.1%	+$6.61K	﹤0.01%	820
2024 Q2	$3.87M	Buy	87,322 +836	+1%	+$38.6K	﹤0.01%	822
2024 Q1	$4.85M	Buy	86,486 +5,155	+6%	+$311K	0.01%	787
2023 Q4	$4.89M	Buy	81,331 +13,849	+21%	+$878K	0.01%	798
2023 Q3	$4.53M	Buy	+67,482	New	+$4.69M	0.01%	790

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Pictet Asset Management's LEGN Position: Q2 2026 in Review

Pictet Asset Management reduced its Legend Biotech (LEGN) stake by 4.4% in Q2 2026, selling an estimated $117K and leaving 94,397 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #864.

Pictet Asset Management first reported a position in LEGN in Q3 2023 and has held it in 12 quarters since. The position peaked at $6.29M in Q1 2025. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Pictet Asset Management held 94,397 shares of Legend Biotech worth $2.73M as of Q2 2026.
Pictet Asset Management sold 4,324 Legend Biotech shares in Q2 2026, an estimated $117K.
Legend Biotech made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #864 holding.
Pictet Asset Management first reported a position in Legend Biotech in Q3 2023 and has held it in 12 quarters since.
Pictet Asset Management's Legend Biotech position peaked at $6.29M in Q1 2025.
219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.